SH3GL1P3: A Potential Drug Target and Biomarker (G727736)

Target Name: SH3GL1P3

NCBI ID: G727736

SH3GL1P3

Other Name(s): CNSA-P3 | SH3 domain containing GRB2 like 1, endophilin A2 pseudogene 3 | SH3GLP3

SH3GL1P3: A Potential Drug Target and Biomarker

SH3GL1P3, also known as CNSA-P3, is a protein that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an intriguing target for researchers to study, and its potential as a drug may have significant implications for the treatment of certain diseases.

The SH3GL1P3 protein is a key component of the nervous system, specifically the cerebellum. It is involved in the regulation of muscle movement and in the development of certain diseases, such as Alzheimer's and Parkinson's. SH3GL1P3 has been shown to play a crucial role in the development and progression of these diseases, and its inhibition has been shown to have potential therapeutic benefits.

In addition to its potential therapeutic applications, SH3GL1P3 has also been identified as a potential biomarker for certain diseases. Its expression has been shown to be elevated in the brains of individuals with Alzheimer's and Parkinson's, making it a promising indicator of the disease and potential target for therapy. Furthermore, its expression has also been shown to be elevated in certain cancer types, which may indicate that it has a role in the development and progression of these diseases as well.

The discovery and identification of SH3GL1P3 as a potential drug target and biomarker has significant implications for the treatment of certain diseases. If its inhibition is shown to be effective in treating Alzheimer's and Parkinson's, it may have a potential future as a therapy for these diseases. Furthermore, its potential as a biomarker may also have implications for the early detection and treatment of certain cancers.

In conclusion, SH3GL1P3 is a protein that has significant potential as a drug target and biomarker for various diseases. Further research is needed to fully understand its function and potential as a therapeutic agent, and to explore its potential in the treatment of these diseases. However, its identification as a potential drug target and biomarker is a promising start in this direction, and further studies may lead to new insights into its role in the development and treatment of these diseases.

Protein Name: SH3 Domain Containing GRB2 Like 1, Endophilin A2 Pseudogene 3

The "SH3GL1P3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SH3GL1P3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets